Verastem reports 52% ORR in PDAC and 42% ORR in NSCLC for KRAS G12D inhibitor VS-7375

Verastem, Inc.

Phase 1 data from China: 23 PDAC patients had 52% ORR and 100% DCR; 12 NSCLC patients had 42% ORR and 83% DCR.
No dose-limiting toxicities observed across 100-900 mg QD; TRAEs mostly Grade 1/2; no TRAE-related deaths.
U.S. Phase 1/2a study for VS-7375 to start at 400 mg dose; plans to evaluate monotherapy and combinations in pancreatic, colorectal, and NSCLC.
Data presented at ASCO 2025; GenFleet is partner in China; Verastem holds rights in U.S. and other regions.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.